Why did Formosa Pharmaceuticals lift the non-compete restrictions?

Directors Ma Hai-Yi and Lo Li-Chu were required to take on independent director roles at other firms, necessitating the formal lifting of non-compete restrictions.

What was the approval rate for the resolution?

The resolution was passed with 98.72% of the voting rights present at the shareholders' meeting in favor.

Will these appointments affect the company's business?

The disclosure indicates 'not applicable' regarding the impact on the company's finance and business operations.

AI News NQ Analysis

[Formosa Pharmaceuticals] Resolution at the 115th Annual General Shareholders' Meeting to Lift Non-Compete Restrictions for Directors (including Independent Directors) (Correction of Fiscal Year)

NQ Score 77/100

N1 Content Completeness 5

AI Summary (NQ-processed)

At the annual shareholders' meeting on May 25, 115, Formosa Pharmaceuticals approved the lifting of non-compete restrictions for Director Ma Hai-Yi and Independent Director Lo Li-Chu, with a 98.72% approval rate.

AI Analysis

Frequently Asked Questions

Q: Why did Formosa Pharmaceuticals lift the non-compete restrictions?: A: Directors Ma Hai-Yi and Lo Li-Chu were required to take on independent director roles at other firms, necessitating the formal lifting of non-compete restrictions.
Q: What was the approval rate for the resolution?: A: The resolution was passed with 98.72% of the voting rights present at the shareholders' meeting in favor.
Q: Will these appointments affect the company's business?: A: The disclosure indicates 'not applicable' regarding the impact on the company's finance and business operations.